Cargando…

Acute Kidney Injury Associated With Lopinavir/Ritonavir Combined Therapy in Patients With COVID-19

Detalles Bibliográficos
Autores principales:	Binois, Yannick, Hachad, Hafsah, Salem, Joe-Elie, Charpentier, Julien, Lebrun-Vignes, Bénédicte, Pène, Frédéric, Cariou, Alain, Chiche, Jean-Daniel, Mira, Jean-Paul, Nguyen, Lee S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409925/ https://www.ncbi.nlm.nih.gov/pubmed/32838087 http://dx.doi.org/10.1016/j.ekir.2020.07.035

Ejemplares similares

Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19. An alleged past-resolved problem
por: Fresse, Audrey, et al.
Publicado: (2021)

Increased survival of cirrhotic patients with septic shock
por: Sauneuf, Bertrand, et al.
Publicado: (2013)

Platelet transfusions in cancer patients with hypoproliferative thrombocytopenia in the intensive care unit
por: Habr, Bassem, et al.
Publicado: (2015)

Timing and causes of death in septic shock
por: Daviaud, Fabrice, et al.
Publicado: (2015)

Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study
por: Mongardon, Nicolas, et al.
Publicado: (2012)

Pulmonary infections prime the development of subsequent ICU-acquired pneumonia in septic shock
por: Llitjos, Jean-François, et al.
Publicado: (2019)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review
por: Nguyen, Lee S., et al.
Publicado: (2021)

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
por: Ader, Florence, et al.
Publicado: (2021)

Use of Venovenous Extracorporeal Membrane Oxygenation in Critically-Ill Patients With COVID-19
por: Jozwiak, Mathieu, et al.
Publicado: (2020)

SSEP N20 and P25 amplitudes predict poor and good neurologic outcomes after cardiac arrest
por: Benghanem, Sarah, et al.
Publicado: (2022)

Plasma thioredoxin levels during post-cardiac arrest syndrome: relationship with severity and outcome
por: Mongardon, Nicolas, et al.
Publicado: (2013)

Effects of Prone Positioning on Respiratory Mechanics and Oxygenation in Critically Ill Patients With COVID-19 Requiring Venovenous Extracorporeal Membrane Oxygenation
por: Laghlam, Driss, et al.
Publicado: (2022)

Propofol/lopinavir/ritonavir: Bradyarrythmia: case report
Publicado: (2020)

Outcomes related to 4864 pregnancies with exposure to lopinavir/ritonavir (LPV/r)
por: Tookey, Pat, et al.
Publicado: (2014)

Impact of COVID-19 on the association between pulse oximetry and arterial oxygenation in patients with acute respiratory distress syndrome
por: Nguyen, Lee S., et al.
Publicado: (2022)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
por: Ceccaldi, Pierre-François, et al.
Publicado: (2010)

Lopinavir/ritonavir: vomiting and watery diarrhoea: case report
Publicado: (2020)

Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
Publicado: (2020)

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

The administration of lopinavir/ritonavir via an enteral feeding tube()
por: Sirvent Segovia, Alejandro Esteban, et al.
Publicado: (2021)

Risk factors for post-ICU red blood cell transfusion: a prospective study
por: Marque, Sophie, et al.
Publicado: (2006)

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
por: Chandwani, Ashish, et al.
Publicado: (2008)

Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
por: Reyskens, Kathleen M. S. E., et al.
Publicado: (2013)

Hydroxychloroquine/lopinavir/ritonavir: Exanthema and eosinophilia: 12 case reports
Publicado: (2020)

Maculopapular rash in COVID-19 patient treated with lopinavir/ritonavir
por: Mazan, Paula, et al.
Publicado: (2020)

Immunosuppressants/lopinavir/ritonavir interaction: Various toxicities: case report
Publicado: (2020)

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
por: Zhu, Zhen, et al.
Publicado: (2020)

Dexamethasone/hydroxychloroquine/lopinavir/ritonavir: Various toxicities: case report
Publicado: (2021)

Lopinavir/ritonavir/sotalol: Various toxicities: 9 case reports
Publicado: (2021)

Lopinavir/ritonavir delays COVID-19 recovery in paediatric patients
Publicado: (2022)

Severe metabolic acidosis after out-of-hospital cardiac arrest: risk factors and association with outcome
por: Jamme, Matthieu, et al.
Publicado: (2018)

Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022
por: Bihan, Kevin, et al.
Publicado: (2023)

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study
por: Squires, Kathleen E., et al.
Publicado: (2011)

Bench-to-bedside review: Fulfilling promises of the Human Genome Project
por: Chiche, Jean-Daniel, et al.
Publicado: (2002)

Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients
por: Schneider, Johanna, et al.
Publicado: (2021)

Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children
por: Martinez, Beatriz Larru, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_8v6k4nah54bc42fmapt1ojmqb8